Research Associate in Cancer Biology
Overview
The University of Bristol is offering a full-time, fixed-term position as a Research Associate in Cancer Biology within the Department of Biochemistry and Biomedical Sciences in the United Kingdom. This funded New Ideas research project focuses on using splice-switching oligonucleotides for cancer therapeutics, specifically exploring how altering mRNA splicing events can selectively kill cancer cells or sensitize them to chemotherapies. The appointment lasts for up to 12 months.
Who can apply
Candidates must hold a relevant PhD or expect to be awarded one very soon, along with a strong motivation to impact childhood cancer research. Applicants need to possess high-level practical skills in molecular, biochemical, and cell biology techniques, alongside hands-on experience in bioinformatics for proteomics and transcriptomics.
Requirements
The role requires a strong understanding of gene regulation, particularly regulation driven by post-transcriptional mRNA splicing. The selected candidate must demonstrate strong initiative to independently plan, execute, analyze, and present experiments. Required practical proficiencies include chromatin immunoprecipitation, RNA immunoprecipitation, co-immunoprecipitation, quantitative PCR, alternative splicing analysis, western blotting, tissue culture, confocal microscopy, immunocytochemistry, and flow cytometry.
What you get
The position provides a salary ranging from £40,704 to £45,641 per annum at Grade I, based on a full-time work pattern of 35 hours per week over a 12-month fixed-term contract.
Key dates
The application process closes at 23:59 UK time on Monday, November 16, 2026.
About University of Bristol
The University of Bristol is a public red brick research university in Bristol, England, with most of its activity concentrated in the city centre. It traces its roots to University College, Bristol, founded in 1876, and received its royal charter in December 1909 following gifts from the Wills and Fry families. It is a member of the Russell Group, the Coimbra Group and the Worldwide Universities Network.
Source: Wikipedia
Links in this posting
- The project builds on our recently published work demonstrating the spliceosomal vulnerability of neuroblastoma [Bojko etal, Cancer Letters 2024, https://doi.org/10.1016/j.canlet.2024.217263].
- For informal queries please contact: Professor Karim Malik, Professor of Molecular Oncology via email: k.t.a.malik@bristol.ac.uk or tel: +44 (0)117-4550106
- We recently launched our strategy to 2030 tying together our mission, vision and values.